Stock Analyses
Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.
All sectors 6,479
Financial Services 1,900
Healthcare 1,116
Technology 1,079
Industrials 668
Consumer Cyclical 490
Basic Materials 337
Consumer Defensive 248
Communication Services 213
Utilities 183
Energy 165
Real Estate 80
Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
A
Deeply overvalued
AGILENT TECHNOLOGIES, INC.
Price$156.47
Model IV$63.45
P/IV2.36
Premium +147%
Return to IV: -59.4%
Owner yield 2.7%
10-yr IRR -0.6% · steady
Market implies +16.0%/yr
vs model +4.7% · above model
AAPG
Valuation N/A
ASCENTAGE PHARMA GROUP INTERNATIONAL
Price$15.06
Model IV—
P/IV—
AARD
Valuation N/A
Aardvark Therapeutics, Inc.
Price$5.38
Model IV—
P/IV—
ABBV
Overvalued
AbbVie Inc.
Price$263.96
Model IV$208.02
P/IV1.24
Premium +27%
Return to IV: -21.2%
Owner yield 3.9%
10-yr IRR 3.8% · steady
Market implies +7.0%/yr
vs model +4.5% · in line
ABCL
Valuation N/A
AbCellera Biologics Inc.
Price$12.63
Model IV—
P/IV—
Market implies +111.1%/yr
vs model +2.0% · above model
ABEO
Valuation N/A
ABEONA THERAPEUTICS INC.
Price$5.57
Model IV—
P/IV—
Market implies +52.7%/yr
vs model +18.0% · above model
ABOS
Valuation N/A
Acumen Pharmaceuticals, Inc.
Price$2.65
Model IV—
P/IV—
ABT
Fairly valued
ABBOTT LABORATORIES
Price$102.61
Model IV$104.52
P/IV0.82
Discount 2%
Return to IV: +1.9%
Owner yield 3.5%
10-yr IRR 2.0% · steady
Market implies +3.3%/yr
vs model +4.1% · in line
ABUS
Valuation N/A
Arbutus Biopharma Corp
Price$5.06
Model IV—
P/IV—
Market implies +84.2%/yr
vs model +2.0% · above model
ABVC
Valuation N/A
ABVC BIOPHARMA, INC.
Price$1.16
Model IV—
P/IV—
Market implies +64.2%/yr
vs model +2.0% · above model
ABVX
Valuation N/A
Abivax S.A.
Price$105.04
Model IV—
P/IV—
ACAD
Deeply overvalued
ACADIA PHARMACEUTICALS INC
Price$27.29
Model IV$10.33
P/IV2.10
Premium +164%
Return to IV: -62.1%
Market implies +27.4%/yr
vs model +18.4% · above model
ACB
Valuation N/A
AURORA CANNABIS INC
Price$3.87
Model IV—
P/IV—
ACET
Valuation N/A
Adicet Bio, Inc.
Price$9.18
Model IV—
P/IV—
ACHC
Deeply undervalued
Acadia Healthcare Company, Inc.
Price$28.33
Model IV$43.21
P/IV0.54
Discount 34%
Return to IV: +52.5%
Market implies +1.0%/yr
vs model +8.0% · below model
ACHV
Valuation N/A
ACHIEVE LIFE SCIENCES, INC.
Price$7.98
Model IV—
P/IV—
ACIU
Valuation N/A
AC Immune SA
Price$2.63
Model IV—
P/IV—
ACOG
Valuation N/A
Alpha Cognition Inc.
Price$8.83
Model IV—
P/IV—
Market implies +29.9%/yr
vs model +15.0% · above model
ACON
Valuation N/A
Aclarion, Inc.
Price$2.52
Model IV—
P/IV—
Market implies +31.6%/yr
vs model +5.9% · above model
ACONW
Deeply undervalued
Aclarion, Inc.
Price$0.03
Model IV$0.06
P/IV0.43
Discount 57%
Return to IV: +134.4%
Market implies -25.0%/yr
vs model +5.9% · below model
ACRS
Valuation N/A
Aclaris Therapeutics, Inc.
Price$5.50
Model IV—
P/IV—
Market implies +36.5%/yr
vs model +3.7% · above model
ACRV
Valuation N/A
Acrivon Therapeutics, Inc.
Price$1.85
Model IV—
P/IV—
ACTU
Valuation N/A
ACTUATE THERAPEUTICS, INC.
Price$1.07
Model IV—
P/IV—
ACXP
Valuation N/A
Acurx Pharmaceuticals, Inc.
Price$1.39
Model IV—
P/IV—
ADAG
Valuation N/A
Adagene Inc.
Price$3.31
Model IV—
P/IV—
Market implies +44.7%/yr
vs model +2.0% · above model
ADCT
Valuation N/A
ADC Therapeutics SA
Price$1.05
Model IV—
P/IV—
Market implies +11.1%/yr
vs model +15.0% · below model
ADGM
Valuation N/A
Adagio Medical Holdings, Inc.
Price$0.48
Model IV—
P/IV—
Market implies +40.3%/yr
vs model +15.0% · above model
ADIL
Valuation N/A
ADIAL PHARMACEUTICALS, INC.
Price$4.86
Model IV—
P/IV—
ADMA
Deeply undervalued
ADMA BIOLOGICS, INC.
Price$9.11
Model IV$17.37
P/IV0.46
Discount 48%
Return to IV: +90.7%
Market implies -11.2%/yr
vs model +50.0% · below model
ADPT
Valuation N/A
Adaptive Biotechnologies Corp
Price$28.61
Model IV—
P/IV—
Market implies +43.2%/yr
vs model +15.7% · above model
ADTX
Valuation N/A
Aditxt, Inc.
Price$0.00
Model IV—
P/IV—
ADUS
Undervalued
Addus HomeCare Corp
Price$117.07
Model IV$155.68
P/IV0.59
Discount 25%
Return to IV: +33.0%
Owner yield 4.9%
10-yr IRR 12.6% · grower
Market implies +5.0%/yr
vs model +12.3% · below model
ADVB
Valuation N/A
Advanced Biomed Inc.
Price$6.54
Model IV—
P/IV—
ADXN
Valuation N/A
Addex Therapeutics Ltd.
Price$3.40
Model IV—
P/IV—
AEHR
Valuation N/A
AEHR TEST SYSTEMS
Price$93.49
Model IV—
P/IV—
Market implies +58.4%/yr
vs model +37.3% · above model
AEMD
Valuation N/A
AETHLON MEDICAL INC
Price$6.31
Model IV—
P/IV—
Market implies +34.0%/yr
vs model +15.0% · above model
AEON
Valuation N/A
AEON Biopharma, Inc.
Price$0.24
Model IV—
P/IV—
AGEN
Valuation N/A
AGENUS INC
Price$7.85
Model IV—
P/IV—
Market implies +50.1%/yr
vs model +2.0% · above model
AGIO
Valuation N/A
AGIOS PHARMACEUTICALS, INC.
Price$33.07
Model IV—
P/IV—
Market implies +37.8%/yr
vs model +15.0% · above model
AGL
Deeply overvalued
agilon health, inc.
Price$89.16
Model IV$41.18
P/IV2.24
Premium +117%
Return to IV: -53.8%
Market implies +16.7%/yr
vs model +40.5% · below model
AGMB
Valuation N/A
Agomab Therapeutics NV
Price$12.17
Model IV—
P/IV—
AHCO
Deeply undervalued
AdaptHealth Corp.
Price$5.71
Model IV$37.20
P/IV0.27
Discount 85%
Return to IV: +551.5%
Owner yield 25.9%
10-yr IRR 41.3% · moderate
Market implies -19.4%/yr
vs model +8.1% · below model
AIM
Valuation N/A
AIM ImmunoTech Inc.
Price$0.21
Model IV—
P/IV—
Market implies +12.5%/yr
vs model +2.0% · above model
AIRS
Deeply overvalued
Airsculpt Technologies, Inc.
Price$2.31
Model IV$1.76
P/IV3.06
Premium +31%
Return to IV: -23.9%
Market implies +8.6%/yr
vs model +3.3% · above model
AKAN
Valuation N/A
AKANDA CORP.
Price$3.22
Model IV—
P/IV—
AKBA
Deeply overvalued
Akebia Therapeutics, Inc.
Price$0.92
Model IV$0.64
P/IV1.64
Premium +43%
Return to IV: -30.1%
Market implies +3.5%/yr
vs model +2.0% · in line
AKTS
Valuation N/A
Aktis Oncology, Inc.
Price$21.88
Model IV—
P/IV—
AKTX
Valuation N/A
Akari Therapeutics Plc
Price$9.16
Model IV—
P/IV—
ALC
Deeply undervalued
ALCON INC
Price$65.04
Model IV$213.61
P/IV0.31
Discount 70%
Return to IV: +228.4%
Owner yield 6.2%
10-yr IRR 18.2% · grower
Market implies +1.1%/yr
vs model +21.9% · below model
ALDX
Valuation N/A
Aldeyra Therapeutics, Inc.
Price$1.36
Model IV—
P/IV—
ALEC
Valuation N/A
Alector, Inc.
Price$1.91
Model IV—
P/IV—
Market implies +80.3%/yr
vs model +2.0% · above model
ALGN
Deeply overvalued
ALIGN TECHNOLOGY INC
Price$147.61
Model IV$54.97
P/IV3.18
Premium +169%
Return to IV: -62.8%
Owner yield 5.4%
10-yr IRR 8.8% · steady
Market implies +19.0%/yr
vs model +5.7% · above model
ALGS
Valuation N/A
Aligos Therapeutics, Inc.
Price$5.24
Model IV—
P/IV—
Market implies +50.7%/yr
vs model +15.0% · above model
ALKS
Fairly valued
Alkermes plc.
Price$43.39
Model IV$45.18
P/IV0.56
Discount 4%
Return to IV: +4.1%
Owner yield 5.6%
10-yr IRR 10.6% · moderate
Market implies +5.3%/yr
vs model +7.1% · in line
ALLO
Valuation N/A
Allogene Therapeutics, Inc.
Price$1.69
Model IV—
P/IV—
Market implies +150.0%/yr
vs model +15.0% · above model
ALLR
Valuation N/A
Allarity Therapeutics, Inc.
Price$1.21
Model IV—
P/IV—
Market implies +64.3%/yr
vs model +15.0% · above model
ALMR
Valuation N/A
Alamar Biosciences, Inc.
Price$34.85
Model IV—
P/IV—
ALMS
Valuation N/A
ALUMIS INC.
Price$7.77
Model IV—
P/IV—
Market implies +46.9%/yr
vs model +15.0% · above model
ALNT
Deeply overvalued
ALLIENT INC
Price$100.49
Model IV$33.31
P/IV2.38
Premium +202%
Return to IV: -66.8%
Owner yield 2.3%
10-yr IRR 0.3% · moderate
Market implies +22.4%/yr
vs model +8.8% · above model
ALNY
Deeply undervalued
ALNYLAM PHARMACEUTICALS, INC.
Price$239.56
Model IV$347.64
P/IV0.87
Discount 31%
Return to IV: +45.1%
Market implies -10.5%/yr
vs model +44.8% · below model